Intellia Therapeutics Inc (NASDAQ: NTLA) is -22.00% lower on its value in year-to-date trading and has touched a low of $8.96 and a high of $33.28 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The NTLA stock was last observed hovering at around $9.45 in the last trading session, with the day’s loss setting it -0.35%.
Currently trading at $9.10, the stock is -13.15% and -16.03% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 5.94 million and changing -3.76% at the moment leaves the stock -50.27% off its SMA200. NTLA registered -71.68% loss for a year compared to 6-month loss of -60.46%.
The stock witnessed a -11.87% gain in the last 1 month and extending the period to 3 months gives it a -40.20%, and is -15.08% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.05% over the week and 8.16% over the month.
Intellia Therapeutics Inc (NTLA) has around 403 employees, a market worth around $941.49M and $57.88M in sales. Profit margin for the company is -896.77%. Distance from 52-week low is 1.51% and -72.67% from its 52-week high. The company has generated returns on investments over the last 12 months (-48.88%).
with sales reaching $11.96M over the same period.The EPS is expected to grow by 11.20% this year, but quarterly earnings will post -15.18% year-over-year. Quarterly sales are estimated to shrink -58.66% in year-over-year returns.
Intellia Therapeutics Inc (NTLA) Top Institutional Holders
The shares outstanding are 102.03M, and float is at 97.77M with Short Float at 24.98%.
The top institutional shareholder in the company is ARK INVESTMENT MANAGEMENT LLC with over 11.6 million shares valued at $259.51 million. The investor’s holdings represent 11.9575% of the NTLA Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 9.6 million shares valued at $$214.79 million to account for 10.0496 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 9.1 million shares representing 9.5287% and valued at over $203.66 million, while DEEP TRACK CAPITAL, LP holds 4.9497 of the shares totaling 4.8 million with a market value of $107.42 million.
Intellia Therapeutics Inc (NTLA) Insider Activity
A total of 0 insider transactions have happened at Intellia Therapeutics Inc (NTLA) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider sale by Clark Eliana,the company’sEVP, Chief Technical Officer. SEC filings show that Clark Eliana sold 679 shares of the company’s common stock on Mar 04 ’25 at a price of $8.99 per share for a total of $6104.0. Following the sale, the insider now owns 95369.0 shares.
Intellia Therapeutics Inc disclosed in a document filed with the SEC on Mar 04 ’25 that BASTA JAMES (EVP, General Counsel) sold a total of 2,572 shares of the company’s common stock. The trade occurred on Mar 04 ’25 and was made at $8.99 per share for $23122.0. Following the transaction, the insider now directly holds 0.11 million shares of the NTLA stock.
Still, SEC filings show that on Jan 29 ’25, Bhanji Muna (Director) disposed off 265 shares at an average price of $9.97 for $2642.0. The insider now directly holds 19,468 shares of Intellia Therapeutics Inc (NTLA).
Intellia Therapeutics Inc (NTLA): Who are the competitors?
The company’s main competitors (and peers) include Palvella Therapeutics Inc. (PVLA) that is trading 53.02% up over the past 12 months. Plandai Biotechnology Inc. (PLPL) that is -99.38% lower over the same period.
